Nadia Hindi

21PUBLICATIONS
94CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsComparative language studiesPredictive and prognostic markersTraditional, complementary and integrative medicine not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Mar 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.

Javier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge

|Jan 20, 2026
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.

Javier Martin-Broto, Antonio Casado, Gloria Marquina

|Jan 15, 2026
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

David S Moura, Jesus Lopez-Marti, Hussein Tawbi

|Dec 15, 2025
Histopathologic Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network Experience.

Alberto Righi, Marco Gambarotti, Rafael Ramos

|Oct 02, 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).

Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura

|Sep 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial.

David S Moura, Jesus M Lopez-Marti, Iva Benesova

Pageof 4

Frequent Collaborators

18 joint publications

Javier Martin-Broto

11 joint publications

David S Moura

5 joint publications

Antonio Gutierrez

5 joint publications

Javier Martinez-Trufero